Scaling Knowledge With AI: Bill Morice, M.D., Ph.D.

Answers from the Lab

Player FM - Internet Radio Done Right

24 subscribers

הוסף לפני four שנים

תוכן מסופק על ידי Mayo Clinic Laboratories. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי Mayo Clinic Laboratories או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.

The Innovators & Investors Podcast

1
Venture Investing in Mobility + Tech with University of Michigan’s Early-Stage Zell Lurie Commercialization Fund 39:30

לפני 22 ימים39:30

הפעל מאוחר יותר

רשימות

לייק

אהבתי

39:30

In this episode of The Innovators & Investors Podcast, host Kristian Marquez sits down with David Brem, Managing Director of the University of Michigan’s Zell Lurie Commercialization Fund. David offers a rare glimpse into the inner workings of a student-led endowment fund focused on early-stage, sector-agnostic investments primarily in the Michigan ecosystem. He shares insights on their unique, founder-first investment approach, how they navigate pre-seed to Series A venture opportunities, and the rigorous due diligence process involving qualitative analysis over pure numbers. David also discusses his roles with global VC networks including Electro Ventures, the London Venture Capital Network, and Level Up Ventures, illustrating how he bridges U.S., European, and Australian venture ecosystems with a special focus on mobility and transportation tech. Highlights include deep dives into emerging trends like eVTOLs (electric vertical takeoff and landing aircraft), smart city infrastructure, and safety innovations in aviation technology. Listeners will gain valuable perspectives on how diverse expertise—from military intelligence and management consulting to academic ventures—shapes David’s investment thesis and community-building efforts. The episode also explores the importance of networking, adding value in the startup ecosystem, and practical advice for aspiring investors or entrepreneurs navigating the venture capital world. With stories of successes, challenges, and future outlooks, this episode is a must-listen for innovators, founders, and investors aiming to understand the intersection of academia, technology, and venture capital in today’s dynamic landscape. Learn more about David's work at https://zli.umich.edu/zell-lurie-commercialization-fund/ Connect with David on LinkedIn at https://www.linkedin.com/in/david-lowell-brem/ Think you'd be a great guest on the show? Apply at https://finstratmgmt.com/innovators-investors-podcast/ Want to learn more about Kristian Marquez's work? Check out his website at https://finstratmgmt.com…

לפני שנה 13:48

MP3•בית הפרקים

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how healthcare is a logical space to apply artificial intelligence (AI) technology and trends in how AI is being utilized.

Their discussion includes:

The benefits and pitfalls of using AI in clinical settings.
Important factors to consider before implementing AI tools in the laboratory.
A successful AI use case from the Parasitology Lab at Mayo Clinic, and how it enhanced turnaround times and staff satisfaction.

358 פרקים

#Science #Fitness #Medicine #Mayo Clinic Podcast For Laboratory #Laboratory Medicine #Healthcare #Lab #Mayo Clinic #Clinical #Dlmp #Morice #Pritt

Scaling Knowledge With AI: Bill Morice, M.D., Ph.D.

Answers from the Lab

24 subscribers

published לפני שנה

שתפו

MP3•בית הפרקים

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how healthcare is a logical space to apply artificial intelligence (AI) technology and trends in how AI is being utilized.

Their discussion includes:

The benefits and pitfalls of using AI in clinical settings.
Important factors to consider before implementing AI tools in the laboratory.
A successful AI use case from the Parasitology Lab at Mayo Clinic, and how it enhanced turnaround times and staff satisfaction.

358 פרקים

#Science #Fitness #Medicine #Mayo Clinic Podcast For Laboratory #Laboratory Medicine #Healthcare #Lab #Mayo Clinic #Clinical #Dlmp #Morice #Pritt

כל הפרקים

Answers from the Lab

1
How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D. 14:23

לפני 12 ימים14:23

14:23

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed . They explore: The significant interest in diagnostics for the advancement of cancer care. The Joint Commission’s collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence. The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality. The role of laboratorians in guiding the ethical and effective use of data and emerging technologies — and what this means for educating future healthcare professionals. The critical importance of values and ethics in deploying new tools.…

Answers from the Lab

1
Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D. 6:51

לפני 14 ימים6:51

6:51

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay ( Mayo ID: LBCS ) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound. (00:32) Can you tell us a little bit about yourself and your background? (01:33) Could you give us a brief overview of this assay? (02:47) Which patients should have this testing, and when should it be performed? (03:48) How would the results be used in patient care?…

Answers from the Lab

1
Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D. 11:49

לפני 21 ימים11:49

11:49

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed. Speaker 3: (00:33) Could you tell us a little about yourselves and your backgrounds? Speaker 3: (01:41) Dr. Taler, could you provide us with a brief background on resistant hypertension? Speaker 3: (03:43) Can you provide a little bit more background on patients who aren't taking their medications? Speaker 3: (05:11) How do physicians currently assess whether patients are taking their medications? Speaker 3: (07:03) Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension? Speaker 3: (09:43) Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?…

Answers from the Lab

1
Advancing Neuropathy Diagnosis With Laboratory Testing and Algorithms: Div Dubey, M.B.B.S 16:20

לפני 26 ימים16:20

16:20

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S. , a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers: The high prevalence of peripheral neuropathy and why early diagnosis is important. The complexities involved in diagnosing the condition. Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process. How algorithms are enhancing the use of testing to complement other diagnostic tools. Ongoing discovery related to specific antibodies associated with neuropathies. Learn more in our e-book, " Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach ."…

Answers from the Lab

1
Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D. 12:21

לפני 28 ימים12:21

12:21

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay ( Mayo ID: ADVQU ) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children. (01:14) Could you give us a brief overview of this assay? (02:06) Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method? (04:00) When is this test typically ordered for transplant patients? Is it used throughout their treatment? (06:56) Could an immunocompromised person be unknowingly infected? (07:31) Is our quantitative method approved for pediatric patients? (08:00) How are the test results used to treat patients? (10:36) What other infections might providers consider alongside adeovirus?…

Answers from the Lab

1
Global Diagnostic Trends and What They Mean for Laboratories: Bill Morice, M.D., Ph.D. 14:32

לפני 6 weeks14:32

14:32

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include: Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. Fierce competition in the global manufacturing landscape as new companies enter the market. Geopolitical dynamics influencing where innovations are deployed. Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.…

Answers from the Lab

1
Five Ways Laboratories Maximize Health System Success: Bill Morice, M.D., Ph.D. 22:05

לפני 8 weeks22:05

22:05

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system. They cover how laboratories impact: Growth in revenue Growth in lab charges Growth in ancillary services Hospital length of stay Control over expenses You can also find more in-depth information on this topic in “ Maximizing your health system’s financial performance ,” a white paper with data-driven ways laboratories support their organizations.…

Answers from the Lab

1
Laboratory Medicine Central to Tick-Borne Disease Response: Bill Morice, M.D., Ph.D. 13:40

לפני 10 weeks13:40

13:40

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover: Different diseases patients can get from ticks. Disease prevention, including Dr. Pritt’s A through Z flash cards with tips for people to protect themselves from infectious insects. Laboratory medicine’s valuable role in testing and educating providers to diagnose patients quickly and accurately. Clinical areas most likely to encounter patients with tick-borne diseases. Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories ).…

Answers from the Lab

1
Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders: Bill Morice, M.D., Ph.D. 22:09

לפני 12 weeks22:09

22:09

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion . They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: Details about how the cerebrospinal fluid biomarker test ( Mayo ID: ASYNC ) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes. Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians. Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN.…

Answers from the Lab

1
Reflex Test Guides Precise Care for Arsenic Exposure: Paul Jannetto, Ph.D. 10:34

לפני 13 weeks10:34

10:34

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk. (00:33) Do you mind telling us a little bit about yourself and your background? (01:45) Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation? (05:25) Which patients should have this testing, and when should it be performed? (06:57) What alternative test options are available, and how does testing at Mayo Clinic compare? (08:37) How are the results used in patient care?…

Answers from the Lab

1
What Happens Next? Lab-Developed Test Rule Vacated: Bill Morice, M.D., Ph.D. 12:05

לפני 14 weeks12:05

12:05

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT). They covered: Details about the ruling to vacate the FDA’s rule on LDT oversight. What LDT oversight might look like in the future. How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation.…

Answers from the Lab

1
Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP 15:20

לפני 14 weeks15:20

15:20

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ. (00:32) Could you provide us a with little bit about your background and yourself? (03:45) Will you please provide a brief overview of Mayo test 3A5Q? (06:56) Which patients should have this testing, and when should it be performed? (08:15) What alternative or complementary tests should be considered? (09:25) How are the results used in patient care? (10:38) Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection? (12:53) What alleles are included in this test?…

Answers from the Lab

1
Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D. 11:09

לפני 15 weeks11:09

11:09

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence , to discuss liquid biopsy cancer testing . Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA. During their conversation, Dr. Morice and Dr. Tan explore: Inspiration for developing the liquid biopsy. Features that differentiate LiquidHALLMARK® from existing cancer tests. Patients who will benefit from the test and how an oncologist might use the results. The future potential of liquid biopsy advancements.…

Answers from the Lab

1
The Emergence of Retail Health: Bill Morice, M.D., Ph.D. 14:15

לפני 16 weeks14:15

14:15

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the evolution of retail health. They cover several key topics, including: The emergence of retail health locations. Three types of care that are well-suited for a retail approach to healthcare. The importance of incorporating diagnostics when designing retail health. Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X .…

Answers from the Lab

1
Significant Infectious Disease Activity Continues: Bill Morice, M.D., Ph.D. 14:00

לפני 18 weeks14:00

14:00

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss infectious disease activity around the nation. They cover: The high prevalence of influenza A, avian influenza, measles, and COVID-19. Reliable resources for information on the spread of infectious diseases. Prevention measures and their impact on the spread of infectious diseases. The risks associated with multiple infectious diseases circulating simultaneously at high rates.…

ברוכים הבאים אל Player FM!

Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.